The breast implant is a foreign body that stimulates a “walling-off” response associated with scar formation (fibroblast proliferation). It has been presumed that inflammatory cells, extracellular matrix, and fibroblast proliferation are responsible for capsule contracture following breast augmentation. The possible causes of capsule contracture are described, and nonsurgical methods for relief of the capsule contracture are discussed.
Methods:
The literature was reviewed for medications and other nonsurgical methods that may possibly be used for relief of capsule contracture or reduction of the incidence of capsule contracture.
Conclusion:
Additional studies are needed that address the effects of drugs and electrostimulation on capsule contracture following breast augmentation.
Get full access to this article
View all access options for this article.
References
1.
PiscatelliSJPartingtonMHubarCGregoryPSiebertJW. Breast capsule contracture: Is fibroblast activity associated with severity?Aesthetic Plast Surg. 1994;18(1):75–79.
2.
RudolphRAbrahamJVecchioneTGuberSWoodwardM. Myofibroblasts and free silicon around breast implants. Plast Reconstr Surg. 1978;62(2):185–196.
3.
BarkerDERetskyMISchultzS. “Bleeding” of silicone from bag-gel breast implants, and its relation to fibrous capsule reaction. Plast Reconstr Surg. 1978;61(6):836–841.
4.
CourtissEHGoldwynRMAnastasiGW. Fate of breast implants with infections around them. Plast Reconstr Surg. 1979;63(6):812–816.
IannelloSMilazzoPBordonaroFBelfioreF. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid—two case reports and literature review. Med Gen Med. 2006;8(4):60.
8.
WangLNTaoLJNingWB. Effect of enalapril on renal interstitial fibrosis in rats with unilateral ureteral obstruction [in Chinese]. Zhong Nan Da Xue Bao Yi Xue Ban. 2008;33(9):841–848.
9.
ZimmanOAToblliJStellaIFerderMFerderLInserraF. The effects of angiotensin-converting-enzyme inhibitors on the fibrous envelope around mammary implants. Plast Reconstr Surg. 2007;120(7):2025–2033.
El-MedanyAHagarHHMoursiMAt MuhammedREl-RakhawyFIEl-MedanyG. Attenuation of bleomycin-induced lung fibrosis in rats by mesna. Eur J Pharmacol. 2005;509(1):61–70.
15.
Zini C, Baccui S, Gandolfi A, Piazza F, Pasanisi E, inventors. Use of Sodium 2-Mercaptoethanesulfonate in Surgery. European Patent # EP0930878. June 26, 2002. Available at: http://freepatentsonline.com/EP0930878. Accessed May 1, 2009.
16.
BrownDTPotsicWPMarshRRLittM. Drugs affecting clearance of middle ear secretions: A prospective for the management of otitis media with effusion. Ann Otol Rhinol Laryngol Suppl. 1985;117:3–15.
17.
SumiyamaKGastoutTJRajanEBakkenTAKnopschieldMA. Chemically assisted endoscopic mechanical submucosa dissection by using mesna. Gastrointest Endosc. 2008;67(3):534–538.
18.
AjmalNRiordanCLCardwellNNanneyLBShackRB. The effectiveness of sodium 2-mercaptoethane sulfonate (mesna) in reducing capsular formation around implants in a rabbit model. Plast Reconstr Surg. 2003;112(5):1455–1461.
LipkowitzMANavaraT. The Encyclopedia of Allergies. 2nd ed.New York, NY: Facts on File Inc; 2001:178.
21.
IzumoTKondoMNegaA. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 2007;80(20):1882–1886.
22.
AndersonRTheronAJGravettCMSteelHCTintingerGRFeldmanD. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol. 2009;156(1):105–115.
23.
TolazziARTolazziKDGarciaM, Influence of leukotriene inhibitor montelukast on wound contraction and cutaneous healing in rats. Aesthetic Plast Surg. 2009;33(1):84–89.
24.
El-SwefySHassanenSI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol. 2009;8(1):41–49.
25.
EMEA. Public Summary of Positive Opinion for Orphan Designation of Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis. EMEA/comp/198295/2004. July 1, 2005. Available online at www.emea.europa.eu/pdfs/human/comp/opinion/1982950. Accessed May 1, 2009.
LiuHDrewPGaugierACChengYVisnerGA. Pirfenidone inhibits lung allograft fibrosis through L-argenine-arginase pathway. Am J Transplant. 2005;5(6):1256–1263.
29.
AntoniuSA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2006;15(7):823–828.
30.
GosselinLEWilliamsJEPersoniusKFaarkasGA. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: Impact of pirfenidone. Muscle Nerve. 2007;35(2):208–215.
31.
NakayamaSMukaeHSakamotoN, Pirfenidone inhibits expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82(3–4):210–217.
ScuderiNMazzochiMFioramontiPBistoniG. The effects of zafirlukast on capsular contracture: Preliminary report. Aesthetic Plast Surg. 2006;30(5):513–520.
38.
ScuderiNMazzocchiMRubinoC. Effects of zafirlukast on capsular contracture: Controlled study measuring the mammary compliance. Int J Immunopathol Pharmacol. 2007;20(3):577–584.
39.
DiAndreaFNoclettiGFGrellaE, Modification of cysteinyl leukotriene receptor expression in capsular contracture: Preliminary results. Ann Plast Surg. 2007;58(2):212–214.
40.
SpanoAPalmeiraBTaidelliTPNavaMB. Reduction of capsular thickness around silicone breast implants by zafirlukast in rats. Eur Surg Res. 2008;41(1):8–14.
41.
MoreiraMFagundesDJde Jesus SimöesMde OliveiraMCPrevidelliIT Dos SantosMoreiraAC. Zafirlukast pocket delivery impairs the capsule healing around textured implants in rats. Aesthetic Plast Surg. 2009;33(1):90–97.
42.
Cardena-CamarenaLPailletJCBriseñoR. Electrostimulation: Uses and applications for periprosthetic capsular contracture: Experimental model. Aesthetic Plast Surg. 2005;29(5):410–414.
43.
EisenbergHVBartelsRJ. Rupture of a silicone bag-gel breast implant by closed compression capsulotomy: Case report. Plast Reconstr Surg. 1977;59(6):849–850.
44.
AddingtonDBMallinRE. Closed capsulotomy causing fractures of the scar capsule and the silicone bag of a breast implant: Case report. Plast Reconstr Surg. 1978;62(2):300–301.
45.
CapozziADu BouRPennisiVR. Distant migration of silicone gel from a ruptured implant: Case report. Plast Reconstr Surg. 1978;62(2):302–303.
46.
SilversmithPE. Ultrasound for capsular contracture of the breast. Plast Reconstr Surg. 1984;73(3):500.
47.
HerhahnFT. Ultrasound and capsular contracture. Plast Reconstr Surg. 1984;74(4):574.
48.
PlanasJMiglianoEWagenfuhrJJrCastilloS. External ultrasonic treatment of capsular contractures in breast implants. Aesthetic Plast Surg. 1997;21(6):395–397.
49.
PlanasJCervelliVPlanasG. Five-year experience on ultrasonic treatment of breast contractures. Aesthetic Plast Surg. 2001;25(2):89–93.
50.
PlanasJ. Prophylactic use of external ultrasound for breast implant capsular contracture. Aesthet Surg J. 2002;22(2):205–207.
51.
MendesFHVireboFDeLuccaL. The influence of external ultrasound on the histologic architecture of the organic capsule around smooth silicone implants: Experimental study in rats. Aesthetic Plast Surg. 2008;32(3):442–450.
52.
del YerroJL. The influence of external ultrasound on the histologic architecture or organic capsule around smooth silicone implants: Experimental study in rats. Aesthetic Plast Surg. 2008;32(3):451–452.
53.
RohrichRKenkelJAdamsW. Preventing capsular contraction in breast augmentation: In search of the Holy Grail. Plast Reconstr Surg. 1999;103(6);1759–1760.
54.
SchlesingerLEllenbogenRDesvigneMSvehlakSHeckR. Zafirlukast (Accolate): A new treatment for capsular contracture. Aesthet Surg J. 2002;22(4);329–336.
55.
GryskiewiczJ. Investigation of Accolate and Singulair for treatment of capsular contracture yields safely concerns. Aesthet Surg J. 2003;23(2);98–101.
56.
ArkedaniG, Treatment of a post-burn keloid with topical captopril: Report of the first case. Plast Reconstr Surg. 2009;123(3);112e–113e.
57.
Ruiz-de-ErenchunR, Use of TGF-B1 inhibitor peptide reduces periprosthetic fibrosis significantly. Plast Reconstr Surg. 2005;116(5);1370–1378.
